SCHEMBL6943644

SCHEMBL6943644

O=C(NCc1ccc2ccccc2n1)c1cc([N+](=O)[O-])ccc1N[C@H]1CC[C@@H](O)CC1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 2/20 0.52
TYRO3 Q06418 2/20 0.52
MERTK Q12866 2/20 0.52
GAS6 Q14393 2/20 0.52
MAPT P10636 5/20 0.49
KMT2A Q03164 4/20 0.44
HDAC1 Q13547 2/20 0.41
HDAC2 Q92769 2/20 0.41
MEN1 O00255 2/20 0.40
PKM P14618 2/20 0.39
NPY1R P25929 1/20 0.39
NPY5R Q15761 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
GAA P10253 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
MAPK1 P28482 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6943641 1.00 FLT3 (0.52) FLT3TYRO3MERTKGAS6MAPT
SCHEMBL6937059 0.84 CYP1A2 (0.55) FLT3TYRO3MERTKGAS6MAPT
SCHEMBL6937063 0.84 CYP1A2 (0.55) FLT3TYRO3MERTKGAS6MAPT
SCHEMBL6937256 0.83 MAPT (0.59) MAPTKMT2AMEN1PKMSMN1; SMN2
SCHEMBL6937260 0.83 MAPT (0.59) MAPTKMT2AMEN1PKMSMN1; SMN2
SCHEMBL6943781 0.82 MAPT (0.49) FLT3TYRO3MERTKGAS6MAPT
SCHEMBL6943783 0.82 MAPT (0.49) FLT3TYRO3MERTKGAS6MAPT
SCHEMBL6938997 0.82 MAPT (0.51) FLT3TYRO3MERTKGAS6MAPT
SCHEMBL6938994 0.82 MAPT (0.51) FLT3TYRO3MERTKGAS6MAPT
SCHEMBL6945179 0.81 MAPT (0.47) MAPTKMT2AMEN1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP disclosed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US disclosed
US-6384080-B1 TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase PDE3A, PDE2A, PDE5A FLT3 1209/4885TYRO3 1671/4885MERTK 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.